Travel Award Application site is now open. Use this link to apply
Submit Travel Award Application
Use this link to signup for emails about the meeting. RDmeeting Email list
May 18, 2018
Travel Award Applications due
June 29, 2018
Online Hotel Registration due
June 29, 2018
Online Meeting Registration due to receive discounted rate
June 29, 2018
Online Abstract Submission due
Sept. 03-08, 2018
The XVIIIth International Symposium on Retinal Degeneration Meeting
Sept. 03, 2018
Monday Arrival and Welcome Reception & Dinner
Sept. 08, 2018
Saturday Morning Departure
Sept. 09-12, 2018
ISER XXIIIth Biennial Meeting.
Belfast, Northern Ireland, UK
Be sure to register in time.
As in the past, the RD2018 meeting will consist of 3 days of platform and keynote addresses, 2 extended evening poster sessions, and a social excursion day. Based on submissions to past RD meetings, we anticipate the final scientific program to include approximately 40 presentations selected from submitted abstracts, in addition to the 4 keynote lectures presented by distinguished speakers (see below). The platform presentations will also include several presentations from travel awardees. Those individuals not selected for a platform presentation will be invited to present their research in well-attended poster sessions. We anticipate that approximately 175 posters will be presented during two evening sessions. In addition, posters will be available for viewing during all breaks throughout the meeting.
We anticipate that topics presented at the meeting will include; gene therapy, optogenetic therapy, gene editing, stem cell therapy with various progenitors, chemical approaches, small molecules for neuroprotection, retinal stress responses and other mechanisms of RD.
Keynote lectures: 40 minutes total (30 min. presentation; 10 min. discussion)
Regular podium presentations: 30 minutes total (20 min. presentation; 10 min. discussion)
Travel awardee presentations: 20 minutes total (15 min. presentation; 5 min. discussion)
Keynote speakers for RD2018
We are very happy and proud to announce that the following distinguished scientists, including Nobel Laureate Prof. Dr. Mario Capecchi, have agreed to present their outstanding work during dedicated keynote lectures.
Mario Capecchi, Ph.D.
University of Utah, Salt Lake City, UT, USA.
Distinguished Professor of Human Genetics and Biology. Dr. Capecchi is a member of the National Academy of Sciences and the European Academy of Sciences and most recently, the National Academy of Medicine. The Nobel Prize in Physiology or Medicine in 2007 tops a long list of worldwide awards and recognitions he has received for his scientific achievements. Dr. Capecchi is best known for his pioneering work on the development of gene targeting by homologous recombination in mouse embryo-derived stem cells. This technology allows scientists to create mutations in any desired gene, giving them virtually complete freedom to manipulate the DNA sequence in the genome of living mice. His work revolutionized the study of mammalian biology and is used by scientists worldwide to understand countless diseases.
Rando Allikmets, Ph.D.
The William and Donna Acquavella Professor in the Departments of Ophthalmology and Pathology & Cell Biology, and Director of Research at the Harkness Eye Institute, Columbia University, New York.
Before entering the field of genetics of eye diseases, his main research interests were in human genome and cancer genetics, where he cloned and characterized over 30 genes in the ATP-binding cassette (ABC) transporter superfamily, including several genes involved in human inherited diseases. He determined that one of these genes, ABCA4 (ABCR), was responsible for Stargardt disease and later characterized it as the first gene associated with age-related macular degeneration. Since then one of the major focuses of Dr. Allikmets’ research has been AMD genetics, where he and his colleagues determined a major disease pathway involving two regulators of the alternative complement cascade, complement factor H and factor B. His other long-standing research interests include designing high-tech diagnostic tools for eye diseases, deciphering the pathophysiology of ABCA4/Stargardt disease, finding new retinal disease genes, and therapeutic applications for ABCA4 disease and AMD.
James T. Handa, M.D.
Robert Bond Welch Professor, Johns Hopkins Wilmer Eye Institute, Baltimore, MD, USA.
Dr. Handa is a clinician-scientist who specializes in medical and surgical management of complex vitreoretinal diseases. He is an implanting surgeon for the Argus II implant. His primary research interest is in age-related macular degeneration (AMD), where he has focused his work on the role of oxidative stress, using molecular pathological approaches to understand how oxidative stress triggers the transformation from normal aging to early AMD.
Peter Humphries, Ph.D., MRIA,
Trinity College Dublin.
Pete is a molecular geneticist with major interests in degenerative diseases of the retina. He was elected Fellow of the University of Dublin in1988, Professor of Medical Molecular Genetics in 1991, and is former Head of the Institute of Genetics at Trinity College Dublin. His team reported the localization of genes for autosomal dominant retinitis pigmentosa in 1989, 1991, and 1993 [the genes encoding rhodopsin, RDS-peripherin and IMPDH1]. Recent interests lie in the molecular genetics both of hereditary and multifactorial diseases of the retina, including retinitis pigmentosa, AMD, and glaucoma.